// App-Quantinova.ai

GS4-03 : Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study

Researchers

Presenter

  • Ivana Sestak

Principal Investigators

  • Michael Crager

  • Jack Cuzick

  • Mitchell Dowsett

  • Steven Shak

  • Gong Tang

  • Robert Gray

  • Joseph Sparano

Medical Centers

  • Centre for Cancer Prevention, London, Greater London, United Kingdom

  • Genomic Health, Inc., Redwood City, CA

  • Ralph Lauren Centre for Breast Cancer Research, Royal Marsden, London, United Kingdom

  • University of Pittsburgh, Pittsburgh, PA

  • Dana-Farber Cancer Institute, Boston, MA

  • Albert Einstein College of Medicine, Great Neck, NY

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved